# Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma

> **NCT07634289** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Olivia Newton-John Cancer Research Institute** · enrollment: 40 (estimated)

## Conditions studied

- Relapsed /Refractory DLBCL

## Interventions

- **DRUG:** Glofitamab
- **RADIATION:** Radiotherapy
- **DRUG:** Obinutuzumab
- **OTHER:** 89Zr-Df-crefmirlimab
- **OTHER:** 18F-granzyme B

## Key facts

- **NCT ID:** NCT07634289
- **Lead sponsor:** Olivia Newton-John Cancer Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2031-12
- **Final completion:** 2032-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-06-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07634289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07634289, "Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07634289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*